References
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19: 345–61.
Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 2017; 8:49.
Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol 2018; 57:664–9.
Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 2018; 79: 1081–8.
Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist 2018;23:1119–26.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Wójcik, E., Stefaniak, A. & Szepietowski, J.C. sQuiz your knowledge! Itchy, polymorphic skin lesions in a patient with clear cell renal carcinoma. Eur J Dermatol 30, 769–770 (2020). https://doi.org/10.1684/ejd.2020.3938
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2020.3938